OakChart

Scienture Holdings Inc

SCNXHealthcare·Pharmaceutical Retailers·USA·Nano·NASD·Nov 11 • 3:59 PM ET

3.040.00 (0.00%)
2026-11-12 05:03 CET
Market cap
4.99 USD m
Revenue, TTM
0.34 USD m
Net income, TTM
-2.82 USD m
Free cash flow, TTM
-3.13 USD m
EPS diluted, TTM
-1.78
P/E
-
Compare

Price

SCNX against its 20, 50 and 200-day averages
2050200beat
5.0010.0015.003.3M6.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SCNXclose 3.0420-day 3.1650-day 5.23200-day 8.813.04

84.4% under the 52-week high of 19.47 on 12 Nov 2025. 52-week low 2.64 on 23 Oct 2026. Last 15 sessions, 39.4% high to low

Volume 0.03× normal · the line is the 50-bar volume average

Profile

SCNX
52-week range, 2% of the way up
2.6419.47

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Commack, NY.

Employees9
IPOJan 26, 2009
Beta3.49
ATR, 14d0.34
Rel volume0.03
Short float9.17%
Insider own22.08%
Inst own5.26%

Snapshot

6 groups

Valuation

Index-
Market Cap4.99M
Enterprise Value7.49M
Income-20.55M
Sales0.65M
Book/sh39.03
Cash/sh4.99
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees9
IPOJan 26, 2009

Ratios

P/E-
Forward P/E-
PEG-
P/S7.68
P/B0.08
P/C0.61
P/FCF-
EV/EBITDA-
EV/Sales11.52
Quick Ratio2.97
Current Ratio3.04
Debt/Eq0.17
LT Debt/Eq0.15
Option/ShortNo / Yes

Earnings

EPS (ttm)-45.23
EPS next Y-0.27
EPS next Q-1.57
EPS this Y93.42%
EPS next Y93.92%
EPS next 5Y-
EPS past 3/5Y23.94% 11.34%
Sales past 3/5Y-65.21% -52.10%
EPS Y/Y TTM92.38%
Sales Y/Y TTM-73.18%
EPS Q/Q78.08%
Sales Q/Q3249.96%
EarningsAug 14 BMO
EPS/Sales Surpr.22.22% -

Ownership

Insider Own22.08%
Insider Trans0.00%
Inst Own5.26%
Inst Trans5.99%
ROA-20.29%
ROE-24.07%
ROIC-27.90%
Gross Margin82.75%
Oper. Margin-2648.49%
Profit Margin-3145.84%
SMA20-3.71%
SMA50-41.91%
SMA200-65.48%
Trades-

Technical

Shs Outstand1.64M
Shs Float1.28M
Short Float9.17%
Short Ratio0.61
Short Interest0.12M
52W High19.47 -84.39%
52W Low2.64 15.15%
Volatility6.53% 8.52%
ATR (14)0.34
RSI (14)33.12
Beta3.49
Rel Volume0.03
Avg Volume191.20K
Volume6,507

Performance

Perf Week-11.11%
Perf Month-6.17%
Perf Quarter-73.85%
Perf Half Y-70.27%
Perf YTD-76.16%
Perf Year-83.58%
Perf 3Y-96.59%
Perf 5Y-99.67%
Perf 10Y-99.67%
Recom1.00
Target Price6.00
Prev Close3.04
Price3.04
Change %0.00%

Peers

Mkt cap
TickerCompanyMkt cap
ETONEton Pharmaceuticals Inc1.97B
EBSEmergent Biosolutions Inc310.55M
INDVIndivior Pharmaceuticals Inc5.97B
AYTUAytu BioPharma Inc19.67M
AQSTAquestive Therapeutics Inc449.96M
CPIXCumberland Pharmaceuticals Inc91.70M
SUPNSupernus Inc6.12B
ZVRAZevra Therapeutics Inc705.13M
CINGCingulate Inc67.47M
TNXPTonix Pharmaceuticals Holding Corp75.20M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B

News

latest 14 of 200
  • SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027 (GlobeNewswire)
  • SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth (GlobeNewswire) -17.14%
  • SCIENTURE Announces Arbli Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals (GlobeNewswire) -10.33%
  • Scienture Holdings, Inc. Announces Reverse Stock Split (GlobeNewswire) -31.83%
  • SCIENTURE Expands Commercial Reach of REZENOPY to Addiction Treatment Centers through an Agreement with a Distribution Partner (GlobeNewswire) -6.43%
  • SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 (GlobeNewswire)
  • SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance (GlobeNewswire)
  • Scienture Holdings: Q2 Earnings Snapshot (Associated Press)
  • SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product (InvestorsHub) +10.00%
  • SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY, the Highest Dose FDA-Approved Naloxone Nasal Spray (GlobeNewswire)
  • SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY (naloxone hydrochloride) to Wholesalers (GlobeNewswire)
  • SCIENTURE Expands Arbli Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide (GlobeNewswire)
  • SCIENTURE Secures Formulary Coverage for REZENOPY with a Large National Health Plan and Expands Commercial Team (GlobeNewswire)
  • SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC (ACCESSWIRE)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-1.750-2.250-1.7500.340.001
2026Q12026-05-18-2.000-5.500-2.0940.060.001
2025Q42026-03-30-7.000-7.000-7.0000.000.001
2023Q22023-08-18-72.500-18.750-72.4782.252.061
2023Q12023-05-15-11.250-7.500-25.2712.252.662
2022Q42023-03-27-37.500-22.500-37.2412.532.512
2022Q32022-11-07-22.500-43.125-22.8642.403.302
2022Q22022-07-25-48.750-20.625-49.6763.282.932
2022Q12022-05-09-45.000-36.250-44.0253.242.213
2021Q42022-03-28-37.500-60.000-36.0152.402.101
2021Q32021-10-25-60.000-45.000-59.7982.551.992
2021Q22021-07-26-120-32.500-119.041.902.283
2021Q12021-04-26-30.000-21.250-30.1883.052.74-
2020Q42021-03-29-75.0003.750-107.131.993.422
2020Q32020-10-267.50011.2506.3196.333.012
2020Q22020-07-27-26.2503.750-26.8396.592.152

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2015FY-90.000-56.250-90.0004.994.96
2018FY0.000-0.5853.83-
2019FY-18.750--18.0007.44-
2020FY-123.75-7.500-123.4217.1219.36
2021FY-243.75-266.25-2459.899.60
2022FY-153.75--153.6711.45-
2025FY-67.500-30.500-67.5000.430.60
2026FY--4.440--3.64
2027FY--0.270--15.47
2028FY-1.090--35.20
2029FY-1.920--49.59
2030FY-2.790--64.21

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-221011.221.221.22
2026Q3S2026-08-141011.581.581.58
2026Q3S2026-06-151001.961.961.96
2026Q3S2026-05-181001.961.961.96
2026Q3S2026-03-301001.961.961.96
2026Q3S2026-02-231001.961.961.96
2026Q3R2026-10-22101-1.57-1.57-1.57
2026Q3R2026-08-14110-1.50-1.50-1.50
2026Q3R2026-06-15110-2.00-2.00-2.00
2026Q3R2026-05-18100-4.50-4.50-4.50
2026Q3R2026-03-30100-4.50-4.50-4.50
2026Q3R2026-02-23100-4.50-4.50-4.50
2026Q3E2026-10-22101-1.57-1.57-1.57
2026Q3E2026-08-14110-1.50-1.50-1.50

Estimate history

EPS, annual19.080.585-18-123.42-244.995-153.671-577.063-137.294-67.622-45.2285
Period201720182019202020212022202320242025TTM
EPS, quarterly-203.517-32.601-33.528-20.464-8.127-11.881-4.757-2.094-1.781
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26
Sales, annual2.9313.8327.43617.1239.88910.251.3640.1370.4320.65
Period201720182019202020212022202320242025TTM
Sales, quarterly00.0190.0650.0530.0100.590.0560.344
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26
Shares, annual0.0140.0150.0170.0220.0220.0250.0360.351.6251.643
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0560.0560.3440.350.5010.6450.9251.6251.643
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.340.430.141.3610.259.8917.127.443.83
Cost of Goods Sold Incl. D&A0.470.590.131.314.735.1411.422.570.45
Gross Profit-0.13-0.160.010.055.524.755.714.873.38
Selling, General and Administrative Excl. Other2.5716.0814.714.457.568.817.494.383.47
Research and Development1.171.962.240.00--0.660.650.95
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-2.70-16.24-14.70-4.40-2.04-4.07-1.780.49-0.09
Interest Expense0.274.081.341.140.340.020.030.050.06
Unusual Expense0.0023.192.500.150.051.230.730.800.01
Net Income Before Taxes-2.82-43.51-18.78-8.48-2.40-5.32-2.54-0.280.01
Income Taxes0.00-1.99-0.530.000.000.000.000.000.00
Consolidated Net Income-2.82-41.51-18.24-8.48-2.40-5.32-2.54-0.280.01
Net Income From Continuing Operations-2.82-41.51-18.24-8.48-1.97-5.32-2.54-0.280.01
Net Income-2.82-41.51-18.54-17.64-3.47-5.32-2.54-0.280.01
EPS (Recurring)-1.78-41.17-124.32-573.66-152.13-205.43-98.6917.300.92
EPS (Basic, Before Extraordinaries)-1.78-67.62-137.29-577.06-153.67-245.00-123.42-18.000.63
EPS (Diluted)-1.78-67.62-137.29-577.06-153.67-245.00-123.42-18.000.58
EBITDA-2.24-15.75-14.65-3.35-1.85-3.93-1.680.59-0.09
Non-Operating Income (Expense)0.150.01-0.24-2.790.020.000.000.070.16
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.105.043.630.260.330.320.510.280.17
Price To Earnings Ratio--------2,669.86
Price To Sales Ratio-18.13149.452.910.331.942.385.262.74
Gross Margin82.75-37.144.393.6053.8547.9933.3365.5088.28
Operating Margin-2,648.49-3,763.78-10,758.70-322.36-19.91-41.11-10.406.64-2.29
Net Margin-3,145.84-9,618.03-13,565.57-1,293.15-33.87-53.75-14.81-3.820.24
Shares Outstanding1.641.630.350.040.030.020.020.020.01
Market Capitalization4.994.9952.942.652.1112.0126.6726.896.22

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q32025Q22025Q12024Q42024Q32024Q2
Total Revenue0.340.060.590.000.010.050.060.02
Cost of Goods Sold Incl. D&A0.470.470.020.020.020.050.080.02
Gross Profit-0.13-0.410.57-0.02-0.010.00-0.02-0.00
Selling, General and Administrative Excl. Other2.573.104.935.143.564.223.481.49
Research and Development1.170.790.170.840.570.981.25-
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.70-3.51-4.36-5.16-3.57-4.21-3.50-1.50
Interest Expense0.270.041.800.650.671.010.220.00
Unusual Expense0.00-0.01-2.460.59-1.152.11-0.500.17
Net Income Before Taxes-2.82-3.40-3.61-6.72-3.06-7.34-3.18-1.62
Income Taxes0.000.000.000.000.00-0.530.000.00
Consolidated Net Income-2.82-3.40-3.61-6.72-3.06-6.80-3.18-1.62
Net Income From Continuing Operations-2.82-3.40-3.61-6.72-3.06-6.80-3.18-1.62
Net Income-2.82-3.40-3.61-6.72-3.06-7.16-3.18-1.83
EPS (Recurring)-1.78-2.10-7.03-11.15-10.27-16.24-37.23-30.55
EPS (Basic, Before Extraordinaries)-1.78-2.09-4.76-11.88-8.13-20.46-33.53-32.60
EPS (Diluted)-1.78-2.09-4.76-11.88-8.13-20.46-33.53-32.60
EBITDA-2.24-3.04-4.35-5.14-3.56-4.20-3.48-1.49
Non-Operating Income (Expense)0.150.130.10-0.320.030.000.030.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.100.100.441.620.240.12-0.00
Price To Sales Ratio--24.65114.7292.40387.447.393.55
Gross Margin-36.61-735.3196.21--139.905.32-28.91-3.76
Operating Margin-785.63-6,230.80-739.12--34,814.94-7,939.57-5,392.75-7,998.78
Net Margin-821.32-6,040.42-611.37--29,869.34-13,493.46-4,908.34-9,807.49
Shares Outstanding1.641.630.930.650.500.350.340.06
Market Capitalization4.9911.5819.6516.7818.0252.9465.2314.66

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments6.660.310.001.093.125.922.870.870.18
Short Term Receivables0.735.452.520.630.981.890.790.430.32
Inventories0.210.000.000.070.061.260.060.080.00
Other Current Assets0.260.010.230.300.220.150.080.080.10
Total Current Assets7.875.772.752.094.379.223.801.470.61
Net Property, Plant & Equipment0.040.220.201.121.330.550.930.020.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable5.25--------
Intangible Assets70.9797.770.000.000.000.000.730.730.00
Deferred Tax Assets0.003.066.08------
Other Assets0.050.569.580.500.060.020.110.020.01
Total Assets84.18107.3818.613.715.779.795.572.230.62
Short Term Debt Incl. Current Port. of LT Debt0.022.760.030.360.180.360.090.320.26
Accounts Payable1.442.901.460.530.480.260.330.400.11
Other Current Liabilities1.272.2410.061.260.270.230.100.140.16
Total Current Liabilities2.747.9111.562.150.930.840.520.860.53
Long Term Debt0.000.770.181.221.070.270.910.520.40
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities11.0416.056.08------
Other Liabilities0.283.580.260.000.000.000.000.000.00
Total Liabilities14.0628.3118.073.372.001.111.431.380.93
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity70.1279.070.540.763.778.684.140.84-0.31
Total Shareholders Equity70.1279.070.540.763.778.684.140.84-0.31
Accumulated Minority Interest0.000.000.00-0.420.000.000.000.000.00
Total Equity70.1279.070.540.343.778.684.140.84-0.31
Total Liabilities & Stockholders Equity84.18107.3818.613.715.779.795.572.230.62
Book Value Per Share43.14225.9114.9830.46173.12402.15237.4257.10-21.94
Tangible Book Value Per Share-0.52-53.4314.9830.46173.12402.15195.798.02-21.94
Full-Time Employees9198344743293223
Price to Book Ratio0.080.670.231.513.183.076.497.36-18.02
Return on Assets-43.34-30.43-76.00-41.49-68.33-33.01-7.290.6460.55
Return on Equity-55.65-45.83-1,299.57-86.72-85.40-39.57-11.413.39-
Return on Invested Capital-59.20-23.22-2,452.01-175.05-109.83-28.33-5.630.66313.71
Quick Ratio2.800.730.240.944.669.467.191.611.16
Current Ratio2.880.730.240.984.7210.957.301.701.16

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-2.82-43.51-18.78-8.48-2.40-5.32-2.54-0.280.01
Depreciation0.460.490.051.050.190.140.100.09-
Other Funds (Non Cash)0.1132.707.06-0.310.391.533.821.000.18
Funds from Operations-2.25-10.31-11.67-7.74-1.82-3.651.380.810.19
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.88-3.07-2.605.510.261.08-3.60-0.670.08
Cash from Operating Activities-3.13-13.38-14.27-2.23-1.56-2.57-2.210.140.27
Capital Expenditures0.000.00-0.010.000.00-0.02-0.04-0.08-0.02
Net Assets From Acquisitions0.000.000.00-0.340.000.000.000.00-0.25
Sale of Fixed Assets and Businesses0.000.000.130.000.000.000.00--
Purchase or Sale of Investments0.000.000.000.000.000.000.00-0.250.00
Purchase of Investments0.000.000.000.000.000.000.00-0.250.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.00-2.500.00-0.430.000.000.000.00
Other Sources0.000.0029.930.070.000.000.000.000.00
Cash from Investing Activities0.000.0027.55-0.28-0.43-0.02-0.04-0.33-0.27
Cash Dividends Paid0.000.00-14.860.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.000.00
Change in Capital Stock10.5926.290.030.520.130.025.302.460.80
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock10.5926.290.030.520.130.025.302.460.80
Proceedsfrom Stock Options10.5926.290.000.520.130.005.262.460.80
Issuance or Reduction of Debt, Net0.00-6.163.100.250.00-0.230.00-0.26-0.12
Change in Long Term Debt0.00-5.742.950.250.000.000.000.00-0.01
Issuance of Long Term Debt0.003.502.950.400.000.000.000.000.00
Reduction of Long Term Debt0.00-9.240.00-0.150.000.000.000.00-0.01
Net Financing Active Other Cash Flow0.20-0.40-1.250.64-0.170.000.000.000.00
Other Financing Activities Uses0.20-0.40-1.25-1.54-0.990.000.000.000.00
Cash from Financing Activities10.7919.73-12.981.41-0.04-0.215.302.190.68
Net Change in Cash7.666.350.31-1.09-2.03-2.803.052.000.69
Free Cash Flow-3.13-13.38-14.28-2.23-1.56-2.59-2.250.060.26
Price to Free Cash Flow-------657.6840.59
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q32025Q22025Q12024Q4
Cash & Short Term Investments8.193.540.360.022.050.31
Short Term Receivables0.390.720.590.005.355.45
Inventories0.200.210.230.000.000.00
Other Current Assets0.430.250.240.290.430.01
Total Current Assets9.204.731.420.307.835.77
Net Property, Plant & Equipment0.020.020.040.050.200.22
Total Investments and Advances3.010.000.000.000.000.00
Intangible Assets70.0770.5297.7797.7797.7797.77
Deferred Tax Assets--0.530.530.533.06
Other Assets0.000.050.000.580.020.56
Total Assets87.7380.66104.83104.29106.36107.38
Short Term Debt Incl. Current Port. of LT Debt1.120.012.562.542.582.76
Accounts Payable0.921.403.673.143.182.90
Other Current Liabilities0.991.391.122.011.702.24
Total Current Liabilities3.032.807.357.697.467.91
Long Term Debt9.570.000.001.581.230.77
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities11.0411.0413.5213.5213.5216.05
Other Liabilities0.000.001.283.642.983.58
Total Liabilities23.6313.8422.1626.4325.2028.31
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity64.1066.8282.6777.8681.1679.07
Total Shareholders Equity64.1066.8282.6777.8681.1679.07
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity64.1066.8282.6777.8681.1679.07
Total Liabilities & Stockholders Equity87.7380.66104.83104.29106.36107.38
Book Value Per Share39.0341.1189.34120.67162.13225.91
Tangible Book Value Per Share-3.63-2.28-16.32-30.86-33.18-53.43
Full-Time Employees-----19
Price to Book Ratio0.080.170.240.220.220.67
Return on Assets---20.29-33.19-23.84-30.43
Return on Equity---24.07-44.11-30.97-45.84
Return on Invested Capital-3.83-5.09-4.36-8.46-3.72-8.97
Quick Ratio2.971.610.160.041.050.73
Current Ratio3.041.690.190.041.050.73

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q32025Q22025Q12024Q4
Net Income-2.82-3.40-3.61-6.72-3.06-7.34
Depreciation0.460.470.010.020.020.01
Other Funds (Non Cash)0.11-0.001.224.270.442.95
Funds from Operations-2.25-2.94-2.38-2.44-2.61-4.37
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.880.02-0.830.40-0.341.47
Cash from Operating Activities-3.13-2.92-3.21-2.03-2.96-2.91
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.002.50
Purchase of Investments0.000.000.000.000.002.50
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.00-2.50
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock10.590.006.870.004.600.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock10.590.006.870.004.600.00
Proceedsfrom Stock Options10.590.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.00-3.320.000.102.79
Change in Long Term Debt0.000.00-3.330.000.002.64
Issuance of Long Term Debt0.000.000.000.000.002.64
Reduction of Long Term Debt0.000.00-3.330.000.000.00
Net Financing Active Other Cash Flow0.20-0.200.000.000.000.00
Other Financing Activities Uses0.20-0.200.000.000.000.00
Cash from Financing Activities10.79-0.203.550.004.702.79
Net Change in Cash7.66-3.120.34-2.031.74-0.12
Free Cash Flow-3.13-2.92-3.21-2.03-2.96-2.91

Revenue breakdown

United States2024: 136.64K 2025: 431.61K
Total Pharmaceutical Preparations revenue2024: 136.64K 2025: 431.61K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.17%0.1M1.3M190.79K
2026-10-158.27%0.1M1.3M186.67K
2026-09-304.08%0.1M1.3M113.58K
2026-09-154.00%0.0M1.2M104.01K
2026-08-313.27%0.0M1.2M99.27K
2026-08-145.15%0.1M1.2M99.61K
2026-07-314.34%0.1M1.2M60.76K
2026-07-158.41%0.1M1.2M61.66K
2026-06-303.03%0.0M1.2M17.97K
2026-06-153.79%0.0M1.2M22.80K
2026-05-293.01%0.0M1.2M117.83K
2026-05-155.48%0.0M0.8M118.43K
2026-04-306.94%0.1M0.8M120.68K
2026-04-158.25%0.1M0.8M124.69K
2026-03-319.50%0.1M0.9M135.07K
2026-03-1312.79%0.1M0.9M135.68K
2026-02-275.95%0.1M0.9M48.22K
2026-02-1310.14%0.1M0.9M54.47K
2026-01-3010.64%0.1M0.9M251.55K
2026-01-1515.13%0.1M0.9M898.78K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-038-KCurrent report2026-10-28SEC
2026-10-198-KCurrent report2026-10-13SEC
2026-10-078-KCurrent report2026-10-05SEC
2026-09-18DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-18SEC
2026-09-148-KCurrent report2026-09-14SEC
2026-09-08PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-08SEC
2026-08-315Annual statement of changes in beneficial ownership of securities2025-12-31SEC
2026-08-313Initial statement of beneficial ownership of securities2025-03-13SEC
2026-08-208-KCurrent report2026-08-14SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-05-298-KCurrent report2026-05-26SEC
2026-05-228-KCurrent report2026-05-18SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-058-KCurrent report2026-05-05SEC
2026-05-018-KCurrent report2026-04-27SEC
2026-04-3010-K/A2025-12-31SEC
2026-03-3010-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-124Statement of changes in beneficial ownership of securities2024-09-19SEC
2026-03-124Statement of changes in beneficial ownership of securities2024-09-19SEC
2025-11-188-KCurrent report2025-11-17SEC
2025-11-148-KCurrent report2025-11-12SEC
2025-11-14SCHEDULE 13G/ASEC
2025-11-138-KCurrent report2025-11-07SEC
2025-11-1210-QQuarterly report pursuant to Section 13 or 15(d)2025-09-30SEC
2025-11-07424B5SEC
2025-10-308-KCurrent report2025-10-24SEC
2025-10-24424B5SEC
2025-10-248-KCurrent report2025-10-20SEC
2025-10-24DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342025-10-23SEC
2025-10-178-KCurrent report2025-10-14SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC1.26%
GEODE CAPITAL MANAGEMENT, LLC0.82%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.58%
VANGUARD FIDUCIARY TRUST CO0.49%
CITADEL ADVISORS LLC0.41%
HRT FINANCIAL LP0.33%
XTX Topco Ltd0.26%
NORTHERN TRUST CORP0.22%
JANE STREET GROUP, LLC0.19%
UBS Group AG0.16%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND1.00%
Fidelity Extended Market Index Fund0.40%
VANGUARD TOTAL STOCK MARKET INDEX FUND0.25%
Fidelity Total Market Index Fund0.13%
Fidelity Series Total Market Index Fund0.11%
Blackstone Alternative Multi-Strategy Fund-0.02%

OakChart. SCNX. Cached 15 minutes.

Some panels did not load: ratings, insider.